Homepage Top Section1

Inrebic is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). It is a

The late-stage study called PAOLA-1 evaluated Lynparza plus bevacizumab in the first line maintenance setting in comparison to bevacizumab alone in women with advanced ovarian cancer, irrespective of

In this regard, Boehringer Ingelheim and MD Anderson plan to set up a joint Virtual Research and Development Center to facilitate effective data sharing and analysis among themselves.

The United States District Court of New Jersey gave ruling against Sandoz over the validity of the two patents that describe and claim Enbrel and the methods for

As per terms of the merger deal, Cambrex shareholders will secure $60 (£49.3) in cash for each share of Cambrex common stock, representing a 47.1% premium to its

Givosiran, which has been developed to be subcutaneously administered, targets aminolevulinic acid synthase 1 (ALAS1). According to Alnylam, monthly administration of the investigational RNAi therapeutic can potentially reduce

The phase 3 rivipansel evaluating safety, efficacy and time to discharge (RESET) study evaluated 345 patients who were randomised 1:1 to receive rivipansel or placebo, administered intravenously every

The approval was based on data from the phase III ARAMIS trial, which assessed Nubeqa plus androgen deprivation therapy (ADT). According to the company, the trial showed a

The late-stage study called MONARCH 2 met its secondary endpoint of overall survival for Verzenio in combination with the endocrine therapy fulvestrant. The trial involved 669 patients, who